Lamivudine resistance in untreated chronic hepatitis B patients in Turkey

Turkish Journal of Gastroenterology

Volumn 19, Issue 2, 2008, Pages 99-103

  Tunçbilek, Semra ^a   Köse, Şükran ^b   Elaldi, Ahmet ^c   Akman, Sezin ^b  

^a UFUK UNIVERSITY   (Turkey)

^b TEPECIK EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c Clinics of Infectious Diseases   (Turkey)

Author keywords

Genotype D; Hepatitis B; Lamivudine; Untreated; YMDD

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHIONINE; TYROSINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHRONIC HEPATITIS; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HISTOLOGY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SCORING SYSTEM; TREATMENT PLANNING; TURKEY (REPUBLIC); VIRUS INFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AMINO ACID MOTIFS; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TURKEY; VIRAL LOAD; YOUNG ADULT;

EID: 45849086516     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61.
2. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
3. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
4. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
5. Severini A, Liu XY, Wilson JS, et al. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′,3′-dideoxy-3′- thiacytidine. Antimicrob Agents Chemother 1995; 39: 1430-5.
6. Zoulim F, Dannaoui E, Borel C, et al. 2′,3′-dideoxy-beta-L-5- fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother 1996; 40: 448-53.
7. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
8. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Semin Liver Dis 2003; 23: 69-80.
9. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003; 23: 81-8.
10. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
11. Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 2004; 24 Suppl 1: 31-6.
12. Liaw YF. The current management of HBV drug resistance. J Clin Virol 2005; 34 Suppl 1: 143-6.
13. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34: 584-6.
14. Huang ZM, Huang QW, Qin YQ, et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005; 11: 867-70.
15. Matsuda M, Suzuki F, Suzuki Y, et al. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol 2004; 39: 34-40.
16. Locardini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25 Suppl 1: 9-19.
17. Cane PA, Cook P, Ratcliffe D, et al. Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother 1999; 43: 1600-8.
18. Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702-7.
19. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
20. Buster EH, Janssen HL. Antiviral treatment for chronic hepatitis B virus infection - immune modulation or viral suppression? Neth J Med 2006; 64: 175-85.
21. Horgan M, Brannigan E, Crowley B, et al. Hepatitis B genotype and YMDD profiles in an untreated Irish population. J Clin Virol 2006; 35: 203-4.
22. Shin YM, Heo J, Kim GH, et al. Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients. Taehan Kan Hakhoe Chi 2003; 9: 1-9.
23. Huang ZM, Huang QW, Qin YQ, et al. Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population. World J Gastroenterol 2005; 11: 6525-9.
24. Ye XG, Wang RL, Guo HB. Detection and analysis of YMDD mutate genes in patients of chronic hepatitis B before being treated. Zhonghua Jianyan Yixue Zazhi 2002; 25: 248.
25. Lee C-Z, Lee H-S, Huang G-T, et al. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol 2006; 12: 5301-5.
26. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
27. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
28. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80.
29. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
30. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
31. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
32. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005; 42: 173-9.
33. Suzuki F, Akuta N, Suzuki Y, et al. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. J Med Virol 2006; 78: 341-52.
34. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001; 12 Suppl 1: 67-71.